Generation and evaluation of anti-SARS-CoV-2 RBD-S chicken IgY antibodies for passive immunisation research.

Generation and evaluation of anti-SARS-CoV-2 RBD-S chicken IgY antibodies for passive immunisation research.

Publication date: Aug 08, 2026

Coronaviruses (CoVs) cause severe respiratory diseases and continue to pose a significant worldwide health threat. Antibodies that specifically target the structural proteins of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) are crucial for immunological research, development of diagnostic assays, and evaluation of immune responses. Avian egg yolk immunoglobulin Y (IgY) represents a novel approach that has attracted considerable interest due to its strong immunological response, scalability, and excellent safety profile. The study involved generating SARS-CoV-2 receptor-binding domain (RBD)-specific spike (S) IgY antibodies by immunising laying hens with a synthetic RBD epitope. IgY antibodies were extracted from egg yolks using optimised purification methods and subsequently characterised for yield, purity, and antigen specificity. The purified IgY preparations were evaluated and verified for specificity and binding affinity to the target antigen using indirect enzyme-linked immunosorbent assay (ELISA), sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), conventional Western blotting, and automated Jess Western blot analysis. The produced antibodies exhibited targeted recognition of the antigen and were effectively purified with commendable yield and purity, highlighting their potential as a cost-effective, scalable, and dependable source of primary antibodies for immunological research and diagnostic applications. Additional research, including virus-neutralisation and in vivo efficacy assessments, is needed to explore their potential for passive immunisation and various biomedical applications.

Open Access PDF

Concepts Keywords
Affinity COVID-19
Biomedical ELISA
Chicken SARS-CoV-2
Coronaviruses Spike (S)-protein
Immunisation

Semantics

Type Source Name
disease MESH respiratory diseases
disease MESH Severe Acute Respiratory Syndrome
drug DRUGBANK Sodium lauryl sulfate
disease MESH SDS
disease MESH COVID 19
drug DRUGBANK Cysteamine
drug DRUGBANK Coenzyme M
disease MESH respiratory infections
disease MESH serum sickness
disease MESH bleeding
disease MESH viral infection
drug DRUGBANK Aspartame
drug DRUGBANK Phosphate ion
disease MESH PBS
drug DRUGBANK Polyethylene glycol
disease MESH glass
disease MESH dis
drug DRUGBANK Medical air
drug DRUGBANK Human Serum Albumin
drug DRUGBANK Ethanol
drug DRUGBANK Acetic acid
drug DRUGBANK Water
drug DRUGBANK Albendazole
drug DRUGBANK Tretamine
pathway REACTOME Immune System
disease MESH image
drug DRUGBANK Ademetionine
disease MESH cytokine storm
disease MESH lfs
pathway KEGG Viral replication
disease MESH infection
disease MESH Allergy
drug DRUGBANK Hydroxychloroquine
disease MESH NS1
disease MESH dengue
drug DRUGBANK Carboxyamidotriazole
disease MESH swine influenza
disease MESH influenza
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH diarrhea
disease MESH brv

Original Article

(Visited 8 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *